WO2005007149A8 - Ambroxol für die behandlung akuter schmerzen - Google Patents

Ambroxol für die behandlung akuter schmerzen

Info

Publication number
WO2005007149A8
WO2005007149A8 PCT/EP2004/007853 EP2004007853W WO2005007149A8 WO 2005007149 A8 WO2005007149 A8 WO 2005007149A8 EP 2004007853 W EP2004007853 W EP 2004007853W WO 2005007149 A8 WO2005007149 A8 WO 2005007149A8
Authority
WO
WIPO (PCT)
Prior art keywords
ambroxol
treating acute
acute pains
pains
treating
Prior art date
Application number
PCT/EP2004/007853
Other languages
English (en)
French (fr)
Other versions
WO2005007149A1 (de
Inventor
Thomas Weiser
Klaus Klinder
Wolfram Gaida
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Thomas Weiser
Klaus Klinder
Wolfram Gaida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Thomas Weiser, Klaus Klinder, Wolfram Gaida filed Critical Boehringer Ingelheim Int
Priority to EP04741038A priority Critical patent/EP1725225A1/de
Priority to JP2006519880A priority patent/JP2009513551A/ja
Priority to CA002532309A priority patent/CA2532309A1/en
Publication of WO2005007149A1 publication Critical patent/WO2005007149A1/de
Publication of WO2005007149A8 publication Critical patent/WO2005007149A8/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Ambroxol und dessen pharmakologisch verträglichen Salze zur Herstellung eines Arzneimittels zur Behandlung von akutem Schmerz.
PCT/EP2004/007853 2003-07-16 2004-07-15 Ambroxol für die behandlung akuter schmerzen WO2005007149A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04741038A EP1725225A1 (de) 2003-07-16 2004-07-15 Ambroxol für die behandlung akuter schmerzen
JP2006519880A JP2009513551A (ja) 2003-07-16 2004-07-15 急性疼痛の治療のためのアンブロキソール
CA002532309A CA2532309A1 (en) 2003-07-16 2004-07-15 Ambroxol for treating acute pains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10332486A DE10332486A1 (de) 2003-07-16 2003-07-16 Ambroxol für die Behandlung akuter Schmerzen
DE10332486.0 2003-07-16

Publications (2)

Publication Number Publication Date
WO2005007149A1 WO2005007149A1 (de) 2005-01-27
WO2005007149A8 true WO2005007149A8 (de) 2006-10-12

Family

ID=34041911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007853 WO2005007149A1 (de) 2003-07-16 2004-07-15 Ambroxol für die behandlung akuter schmerzen

Country Status (6)

Country Link
US (2) US20050014844A1 (de)
EP (1) EP1725225A1 (de)
JP (1) JP2009513551A (de)
CA (1) CA2532309A1 (de)
DE (1) DE10332486A1 (de)
WO (1) WO2005007149A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
CN101039674A (zh) * 2004-09-21 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗中枢神经源性神经痛
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
EP1714655A1 (de) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1931349A4 (de) * 2005-08-25 2009-08-05 Wex Pharmaceuticals Inc Verwendung von natriumkanalblockern zur behanldung von muskel- und skelettschmerzen
US20100144767A1 (en) * 2005-08-25 2010-06-10 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
CN103271920A (zh) 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途
NZ609742A (en) 2010-12-23 2015-01-30 Lectio Pharmaentwicklungs Und Verwertungs Gmbh Aqueous solution of ambroxol
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
US10309256B2 (en) * 2013-10-15 2019-06-04 United Technologies Corpoation Non-linear bumper bearings
US20150190377A1 (en) * 2014-01-06 2015-07-09 The Regents Of The University Of California, A California Corporation Neuronal regeneration
US10265280B2 (en) 2016-11-14 2019-04-23 Mingwu Wang Formulations for the treatment of ocular surface diseases and related methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568358A (en) * 1896-09-29 Paper-pulp engine
EP0445749B1 (de) * 1990-03-08 1996-07-10 Fujisawa Pharmaceutical Co., Ltd. N-Monosubstituierte Cyclopentenylamine, ein Verfahren zu ihrer Herstellung, und ihre Verwendung als Medikament
CA2038597A1 (en) * 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5612061A (en) * 1994-10-14 1997-03-18 Rabkin; Simon W. Composition and method for the treatment of premenstrual syndrome
WO1996033704A1 (fr) * 1995-04-26 1996-10-31 Taisho Pharmaceutical Co., Ltd. Preparation pour administration orale
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
JP2000080034A (ja) * 1998-09-02 2000-03-21 Taisho Pharmaceut Co Ltd 風邪用組成物
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
DE10203104A1 (de) * 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Ambroxol für die Behandlung chronischer Schmerzen
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
DE10208313A1 (de) * 2002-02-27 2003-09-11 Boehringer Ingelheim Pharma Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum
EP1417961A1 (de) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Neue pharmazeutische Zubereitung enthaltend eine Kombination von Ambroxol oder Bromhexin und Isopropamid Jodid
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen

Also Published As

Publication number Publication date
WO2005007149A1 (de) 2005-01-27
US20080009548A1 (en) 2008-01-10
CA2532309A1 (en) 2005-01-27
EP1725225A1 (de) 2006-11-29
US20050014844A1 (en) 2005-01-20
DE10332486A1 (de) 2005-02-10
JP2009513551A (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
AU2003300791A1 (en) Combination therapy for the treatment of pain
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
AU2003286567A1 (en) Methods for the treatment of skin disorders
SI1531819T1 (sl) Uporaba IxB-kinaznih inhibitorjev pri terapiji bolečin
HK1086027A1 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
IL196301A0 (en) Medicament for the treatment of hapatitis c
WO2005007149A8 (de) Ambroxol für die behandlung akuter schmerzen
EP1648385A4 (de) System und verfahren für die photodynamische behandlung von verbrennungen, wunden und verwandten hauterkrankungen
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
HK1075843A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
AU2003263628A1 (en) Medical treatment system for stimulating spots on the body suitable for acupuncture
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
GB0213869D0 (en) The treatment of pain
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2002083083A3 (en) Pharmaceutically active compounds and methods of use
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
AU2562501A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
AU2003294941A1 (en) Combinations of a vanilloid antagonist and an nsaid for the treatment of pain
MXPA02009434A (es) Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004741038

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2532309

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006519880

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 04/2005 UNDER (71 AND 81) REPLACE "WRONG PUBLISHED DESIGNATIONS" BY "CORRECT DESIGNATIONS"; DUE TO A TRANSFER PROBLEM BY THE PUBLICATION

WWP Wipo information: published in national office

Ref document number: 2004741038

Country of ref document: EP